Eagle Pharmaceuticals, Inc. appoints Abhinav Jain as an independent member of its Board of Directors, with Nantahala Capital Management, LLC, holding approximately 38% of the Company’s shares. Mr. Jain’s strategic insights are expected to enhance value for stakeholders. He has a background in investments, private equity, and structured credit, with degrees from MIT and The Wharton School. The Agreement includes standstill, voting, and other provisions. Eagle Pharmaceuticals focuses on developing innovative medicines to improve patients’ lives and has a pipeline of oncology and critical care products. For more information, visit Eagle’s website.

Contact Lisa M. Wilson for Investor Relations at 212-452-2793 or [email protected].

Read more at GlobeNewswire: Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board